Dr. Alex Waldrop

SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

Biolog specializes in microbial identification, phenotypic cell profiling, and metabolic fingerprinting for microbial and mammalian cells. The company’s products enable the identification of thousands of species of bacteria, yeast, and fungi, as well as the characterization of human cells and mitochondria. Biolog's products are available worldwide, either directly from the company or through its extensive network of international distributors. The company was founded in 1984 and is based in Hayward, California.

April 2004, Sensia spun-off from the technologies developed at the Biosensor Group within the National Microelectronics Centre (CNM) of the Spanish National Research Council (CSIC). Concluding research results and availability of biosensing systems already working at lab level originated the proposal of bringing them into commercialisation, after an initial phase of prototyping and industrialisation. This first idea was supported by Genetrix a young biotech company which is interested in developing biosensors for the characterisation and detection of molecular interactions which are relevant in human pathologies. Dr. Pedro Banda, with experience in the semiconductor industry and biosensor technologies, joined in to get in charge of the project.n

ProteoGen Bio aims to join research and market in the fields of bioinformatics and biotechnology. Established in September 2003 as a spin-off company of the University of Pisa, with its expertise in different areas, and a interdisciplinary approach, ProteoGen Bio is developing technologies for helping modern molecular biology in its multi-purpose applications: from diagnostics to biomedicine, from mass spectrometry to environmental conservation.

The company plan and implement integrated PR-programs and DTC-campaigning for ethical and OTC products as well as conduct medical education programmes for defined target groups. Furthermore, the company support clients with educational advertising for controversial scientific topics and with public affairs and lobbying on a national or an international level. The company also assist in positioning, brand building and launching IPOs for biotech companies as well as in change management and crisis communications for hospitals.

Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.